Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Pyridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.75 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.75 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL1298477 | 1.00 | — | — | |
| Pyridine SCHEMBL1895575 | 0.96 | — | — | |
| Benzene SCHEMBL28210123 | 0.96 | TSHR (0.82) | TSHRNAPRTTDP1NOTUMSLC6A2 | |
| Pyridine SCHEMBL28470067 | 0.96 | TSHR (0.82) | TSHRNAPRTTDP1NOTUMSLC6A2 | |
| Pyridine SCHEMBL6115211 | 0.96 | TSHR (0.82) | TSHRNAPRTTDP1NOTUMSLC6A2 | |
| Pyridine SCHEMBL27791776 | 0.96 | TSHR (0.82) | TSHRNAPRTTDP1NOTUMSLC6A2 | |
| Pyridine SCHEMBL11877627 | 0.96 | TSHR (0.82) | TSHRNAPRTTDP1NOTUMSLC6A2 | |
| Pyridine SCHEMBL23877918 | 0.92 | TSHR (0.75) | TSHRNAPRTTDP1NOTUMSLC6A2 | |
| Pyridine SCHEMBL28572430 | 0.92 | TSHR (0.75) | TSHRNAPRTTDP1NOTUMSLC6A2 | |
| Pyridine SCHEMBL10978290 | 0.92 | TSHR (0.75) | TSHRNAPRTTDP1NOTUMSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120136189-A1 | BUFFERED IONIC LIQUIDS FOR OLEFIN DIMERIZATION | CONOCOPHILLIPS COMPANY - IP SERVICES GROUP (US) | 2012-05-31 | — | — | US | claimed |
| US-20110185788-A1 | IONIC LIQUIDS AS SOLVENTS IN HEADSPACE GAS CHROMATOGRAPHY | KOCH PETER | 2011-08-04 | — | — | US | claimed |
| EP-2275090-A2 | Microparticles prepared using an ionic liquid | Novartis AG (CH) | 2011-01-19 | — | — | EP | claimed |
| US-20100239524-A1 | MICROPARTICLES PREPARED USING AN IONIC LIQUID | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | claimed |
| US-7569149-B2 | Ionic liquids as solvents in headspace gas chromatography | NOVARTIS AG (CH) | 2009-08-04 | — | — | US | claimed |
| US-20060147532-A1 | Microparticles prepared using an ionic liquid | AUSBORN MICHAEL | 2006-07-06 | — | — | US | claimed |
| US-20050205493-A1 | Ionic liquids as solvents in headspace gas chromatography | NOVARTIS AG (CH) | 2005-09-22 | — | — | US | claimed |
| EP-1569621-A1 | MICROPARTICLES PREPARED USING AN IONIC LIQUID | Novartis AG (CH) | 2005-09-07 | — | — | EP | claimed |
| EP-1529205-A2 | ANALYTICAL PROCESS | Novartis AG (CH) | 2005-05-11 | — | — | EP | claimed |
| WO-2004052340-A1 | MICROPARTICLES PREPARED USING AN IONIC LIQUID | NOVARTIS AG (CH) | 2004-06-24 | — | — | WO | claimed |
| WO-2004013612-A2 | IONIC LIQUIDS AS SOLVENTS IN HEADSPACE GAS CHROMATOGRAPHY | NOVARTIS AG (CH) | 2004-02-12 | — | — | WO | claimed |
| WO-2000040673-A1 | INDUSTRIAL PROCESS AND CATALYSTS | THE SECRETARY OF STATE FOR DEFENCE (GB) | 2000-07-13 | — | — | WO | claimed |
| US-5994602-A | IN THE PRESENCE OF A HYDROCARBYL ALUMINUM OR GALLIUM HALIDE AND A HYDROCARBYL-SUBSTITUTED IMIDAZOLIUM OR PYRIDINIUM HALIDE | BP CHEMICALS LIMITED (GB) | 1999-11-30 | — | — | US | claimed |
| WO-1998047616-A1 | CATALYST COMPRISING A BUFFERED IONIC LIQUID AND HYDROCARBON CONVERSION PROCESS, E.G. OLIGOMERISATION | BP CHEMICALS LIMITED (GB) | 1998-10-29 | — | — | WO | claimed |
| EP-0693045-B1 | ALKYLATION PROCESS | BP CHEM INT LTD (GB) | 1997-10-22 | — | — | EP | claimed |
| EP-0791643-A1 | Lubricating oils | BP Chemicals Limited (GB) | 1997-08-27 | — | — | EP | claimed |
| EP-0693045-A1 | ALKYLATION PROCESS | BP CHEM INT LTD (GB) | 1996-01-24 | — | — | EP | claimed |
| WO-1995021872-A1 | IONIC LIQUIDS | BP CHEMICALS LIMITED (GB) | 1995-08-17 | — | — | WO | claimed |
| WO-1995021806-A1 | ALKYLATION PROCESS | BP CHEMICALS LIMITED (GB) | 1995-08-17 | — | — | WO | claimed |
| EP-2593403-B1 | METHOD FOR PRODUCING A GEL FILM AND FILTRATION MEMBRANE PREPARED WITH THIS METHOD | UNIV MONASH (AU) | 2020-03-04 | — | — | EP | disclosed |
| US-10297396-B2 | Graphene-based films | MONASH UNIVERSITY (AU) | 2019-05-21 | — | — | US | disclosed |
| US-9751763-B2 | Material and applications therefor | MONASH UNIVERSITY (AU) | 2017-09-05 | — | — | US | disclosed |
| US-20160016804-A1 | GRAPHENE-BASED FILMS | MONASH UNIVERSITY (AU) | 2016-01-21 | — | — | US | disclosed |
| EP-2964572-A1 | GRAPHENE-BASED FILMS | Monash University (AU) | 2016-01-13 | — | — | EP | disclosed |
| WO-2014134663-A1 | GRAPHENE-BASED FILMS | MONASH UNIVERSITY (AU) | 2014-09-12 | — | — | WO | disclosed |
| US-20130180912-A1 | MATERIAL AND APPLICATIONS THEREFOR | MONASH UNIVERSITY (AU) | 2013-07-18 | — | — | US | disclosed |
| EP-2593403-A1 | MATERIAL AND APPLICATIONS THEREFOR | Monash University (AU) | 2013-05-22 | — | — | EP | disclosed |
| US-8276664-B2 | Well treatment operations using spherical cellulosic particulates | BAKER HUGHES INCORPORATED (US) | 2012-10-02 | — | — | US | disclosed |
| US-20120220775-A1 | ENANTIOSELECTIVE PREPARATION OF QUINOLINE DERIVATIVES | LOHSE OLIVIER (FR) | 2012-08-30 | — | — | US | disclosed |
| US-20120136189-A1 | BUFFERED IONIC LIQUIDS FOR OLEFIN DIMERIZATION | CONOCOPHILLIPS COMPANY - IP SERVICES GROUP (US) | 2012-05-31 | — | — | US | disclosed |
| WO-2012006657-A1 | MATERIAL AND APPLICATIONS THEREFOR | MONASH UNIVERSITY (AU) | 2012-01-19 | — | — | WO | disclosed |
| WO-2011112514-A1 | BUFFERED IONIC LIQUIDS FOR OLEFIN DIMERIZATION | CONOCOPHILLIPS COMPANY (US) | 2011-09-15 | — | — | WO | disclosed |
| US-20110185788-A1 | IONIC LIQUIDS AS SOLVENTS IN HEADSPACE GAS CHROMATOGRAPHY | KOCH PETER | 2011-08-04 | — | — | US | disclosed |
| EP-1613599-B8 | A PROCESS FOR THE PREPARATION OF 5-(HALOACETYL)-8-(SUBSTITUTED OXY)-(1H)-QUINOLIN-2-ONES | NOVARTIS AG (CH) | 2011-06-22 | — | — | EP | disclosed |
| US-20110140885-A1 | SENSOR FOR CONTAINER MONITORING SYSTEM | HUMMER GREGORY J | 2011-06-16 | — | — | US | disclosed |
| EP-2275090-A2 | Microparticles prepared using an ionic liquid | Novartis AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| EP-1613599-B1 | A PROCESS FOR THE PREPARATION OF 5-(HALOACETYL)-8-(SUBSTITUTED OXY)-(1H)-QUINOLIN-2-ONES | NOVARTIS AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| US-20100239524-A1 | MICROPARTICLES PREPARED USING AN IONIC LIQUID | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| EP-1791820-B1 | ENANTIOSELECTIVE PREPARATION OF QUINOLINE DERIVATIVES | NOVARTIS AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| US-7605267-B2 | Process for the preparation of 5-(halocetyl)-8-(substituted oxy)-(1h)-quinolin-2-ones | NOVARTIS AG (CH) | 2009-10-20 | — | — | US | disclosed |
| US-20090199622-A1 | IONIC LIQUIDS AS SOLVENTS IN HEADSPACE GAS CHROMATOGRAPHY | KOCH PETER | 2009-08-13 | — | — | US | disclosed |
| US-7569149-B2 | Ionic liquids as solvents in headspace gas chromatography | NOVARTIS AG (CH) | 2009-08-04 | — | — | US | disclosed |
| US-20090054653-A1 | ENANTIOSELEKTIVE PREPARATION OF QUINOLINE DERIVATIVE | LOHSE OLIVIER | 2009-02-26 | — | — | US | disclosed |
| US-20090044942-A1 | Cellulosic Particulates and Method of Manufacture and Use Thereof | BJ SERVICES COMPANY | 2009-02-19 | — | — | US | disclosed |
| EP-1791820-A2 | ENANTIOSELECTIVE PREPARATION OF QUINOLINE DERIVATIVES | Novartis AG (CH) | 2007-06-06 | — | — | EP | disclosed |
| US-20060189653-A1 | Process for the preparation of 5-(halocetyl)-8-(substituted oxy)-(1h)-quinolin-2-ones | NOVARTIS AG (CH) | 2006-08-24 | — | — | US | disclosed |
| US-20060147532-A1 | Microparticles prepared using an ionic liquid | AUSBORN MICHAEL | 2006-07-06 | — | — | US | disclosed |
| CN-1774423-A | Process for the preparation of 5- (haloacetyl) -8- (substituted oxy) - (1H) -quinolin-2-ones | NOVARTIS AG (CH) | 2006-05-17 | — | — | CN | disclosed |
| EP-1613599-A1 | A PROCESS FOR THE PREPARATION OF 5-(HALOACETYL)-8-(SUBSTITUTED OXY)-(1H)-QUINOLIN-2-ONES | Novartis AG (CH) | 2006-01-11 | — | — | EP | disclosed |
| WO-2005123684-A2 | ENANTIOSELEKTIVE PREPARATION OF QUINOLINE DERIVATIVE | NOVARTIS AG (CH) | 2005-12-29 | — | — | WO | disclosed |
| US-20050205493-A1 | Ionic liquids as solvents in headspace gas chromatography | NOVARTIS AG (CH) | 2005-09-22 | — | — | US | disclosed |
| EP-1569621-A1 | MICROPARTICLES PREPARED USING AN IONIC LIQUID | Novartis AG (CH) | 2005-09-07 | — | — | EP | disclosed |
| EP-1529205-A2 | ANALYTICAL PROCESS | Novartis AG (CH) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004087668-A1 | A PROCESS FOR THE PREPARATION OF 5-(HALOACETYL)-8-(SUBSTITUTED OXY)-(1H)-QUINOLIN-2-ONES | NOVARTIS AG (CH) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004052340-A1 | MICROPARTICLES PREPARED USING AN IONIC LIQUID | NOVARTIS AG (CH) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004013612-A2 | IONIC LIQUIDS AS SOLVENTS IN HEADSPACE GAS CHROMATOGRAPHY | NOVARTIS AG (CH) | 2004-02-12 | — | — | WO | disclosed |
| CN-1058694-C | Alkylation process | BP CHEM INT LTD (GB) | 2000-11-22 | — | — | CN | disclosed |
| WO-2000041809-A1 | IONIC LIQUID CATALYST FOR ALKYLATION | BP CHEMICALS LIMITED (GB) | 2000-07-20 | — | — | WO | disclosed |
| US-5994602-A | IN THE PRESENCE OF A HYDROCARBYL ALUMINUM OR GALLIUM HALIDE AND A HYDROCARBYL-SUBSTITUTED IMIDAZOLIUM OR PYRIDINIUM HALIDE | BP CHEMICALS LIMITED (GB) | 1999-11-30 | — | — | US | disclosed |
| WO-1998047616-A1 | CATALYST COMPRISING A BUFFERED IONIC LIQUID AND HYDROCARBON CONVERSION PROCESS, E.G. OLIGOMERISATION | BP CHEMICALS LIMITED (GB) | 1998-10-29 | — | — | WO | disclosed |
| EP-0693045-B1 | ALKYLATION PROCESS | BP CHEM INT LTD (GB) | 1997-10-22 | — | — | EP | disclosed |
| EP-0791643-A1 | Lubricating oils | BP Chemicals Limited (GB) | 1997-08-27 | — | — | EP | disclosed |
| CN-1123023-A | Alkylation process | BP CHEM INT LTD (GB) | 1996-05-22 | — | — | CN | disclosed |
| EP-0558187-B1 | Butene polymers | BP CHEM INT LTD (GB) | 1996-04-10 | — | — | EP | disclosed |
| EP-0693045-A1 | ALKYLATION PROCESS | BP CHEM INT LTD (GB) | 1996-01-24 | — | — | EP | disclosed |
| WO-1995021806-A1 | ALKYLATION PROCESS | BP CHEMICALS LIMITED (GB) | 1995-08-17 | — | — | WO | disclosed |
| WO-1995021872-A1 | IONIC LIQUIDS | BP CHEMICALS LIMITED (GB) | 1995-08-17 | — | — | WO | disclosed |
| US-5304615-A | Aluminium compounds with imidazolium and pyridinium halides | BP CHEMICALS LIMITED (GB) | 1994-04-19 | — | — | US | disclosed |
| EP-0558187-A1 | Butene polymers | BP Chemicals Limited (GB) | 1993-09-01 | — | — | EP | disclosed |
| EP-0558187-A1 | Butene polymers | BP Chemicals Limited (GB) | 1993-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054653-A1 | ENANTIOSELEKTIVE PREPARATION OF QUINOLINE DERIVATIVE | HAX1, OPRK1, OPRD1 | SLC6A2 580/4885SLC6A4 1634/4885SLC6A3 956/4885 |
| US-20100239524-A1 | MICROPARTICLES PREPARED USING AN IONIC LIQUID | FIBP, MIF, CHMP4B | SLC6A2 4306/4885SLC6A4 3874/4885SLC6A3 4476/4885 |
| US-20120136189-A1 | BUFFERED IONIC LIQUIDS FOR OLEFIN DIMERIZATION | OSBPL8, OSBP, OSBP2 | SLC6A2 2560/4885SLC6A4 2764/4885SLC6A3 3140/4885 |
| US-20120220775-A1 | ENANTIOSELECTIVE PREPARATION OF QUINOLINE DERIVATIVES | OPRM1, OPRD1, HAX1 | SLC6A2 917/4885SLC6A4 2383/4885SLC6A3 1314/4885 |
| US-20060189653-A1 | Process for the preparation of 5-(halocetyl)-8-(substituted oxy)-(1h)-quinolin-2-ones | UGT8, KAT8, UGT1A8 | SLC6A2 770/4885SLC6A4 2349/4885SLC6A3 1573/4885 |
| US-20060147532-A1 | Microparticles prepared using an ionic liquid | FIBP, MIF, CHMP4B | SLC6A2 4306/4885SLC6A4 3874/4885SLC6A3 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.